Last updated: February 20, 2026
What is the Drug Identified by NDC 24689-0102?
NDC 24689-0102 corresponds to Duloxetine Hydrochloride in a 60 mg capsule formulation. It is marketed under the brand name Cymbalta and is used primarily for major depressive disorder, generalized anxiety disorder, fibromyalgia, and neuropathic pain.
Market Overview
Market Size and Demand
- Prevalence of Indications: Major depressive disorder affects approximately 7% of U.S. adults, equating to over 17 million people. Generalized anxiety disorder impacts 3% of adults (~7.7 million). Fibromyalgia affects 2-4% of the population, with a higher prevalence in women.
- Market Penetration: Cymbalta holds approximately 15% of the antidepressant market share in the U.S., with total prescription volume around 10 million units annually (IQVIA, 2022).
Competition Landscape
- Key competitors include Sertraline (Zoloft), Escitalopram (Lexapro), and Venlafaxine (Effexor).
- Generic versions of duloxetine introduced in 2015 have reduced prices but maintained steady demand due to efficacy and tolerability.
Regulatory Status
- Patent expiration: October 2014.
- Generic availability: Multiple FDA-approved generics available since 2015, leading to significant price competition.
- Market Exclusivity: No longer has patent protection; future exclusivity unlikely without new formulation or indication approvals.
Supply Chain and Manufacturers
- Leading manufacturers include Lupin Pharmaceuticals, Teva Pharmaceuticals, and Mylan.
- The drug is distributed via chain pharmacies, hospital formularies, and mail-order services.
Price Dynamics and Trends
Historical Pricing
| Year |
Brand Price per 30-count (60 mg capsules) |
Generic Price per 30-count (60 mg capsules) |
| 2014 |
$300 (brand) |
$250 (generic) |
| 2018 |
$280 |
$60 |
| 2022 |
$275 |
$45 |
- The transition from brand to generic has catalyzed a depreciating trend, with generic prices declining by 80% since 2014.
Current Price Projections
Assumptions:
- No new patent protections or market exclusivity extensions.
- Continued availability of generics.
- Stable demand from existing indications.
Price Outlook (Next 3-5 Years):
| Year |
Estimated Average Price per 30-count (60 mg capsules) |
Rationale |
| 2023 |
$40 |
Slight price decline with market saturation. |
| 2024 |
$35 |
Increased competition and procurement efficiencies. |
| 2025 |
$30 |
Market stabilization; gradual decrease based on generic competition. |
Factors Influencing Price Trajectory
- Market Share of Generics: Dominant, with 90% of prescriptions filled by generics.
- Manufacturing Costs: Declined by 30% since patent expiry, enabling further price reductions.
- Supply Chain Dynamics: Potential for stockpiling or shortages could temporarily affect prices.
- Regulatory Changes: New formulations or indications might influence future pricing.
Future Market Drivers and Risks
Drivers
- Growth in total prescriptions driven by expanding indications.
- Increased adoption for off-label uses, especially pain management.
- Cost reductions in generics encourage wider access, maintaining steady demand.
Risks
- Potential introduction of new competitors or biosimilars.
- Price ceiling constraints due to insurance formularies.
- Regulatory moves to limit off-label use or generic prescribing.
Summary of Key Data Points
- Market size: ~10 million prescriptions/year in the U.S.
- Main competitors: Zoloft, Lexapro, Effexor.
- Market share: Generic duloxetine holds ~90% of prescriptions.
- Price trend: Generic capsule prices have declined by ~80% since 2014.
- Projections: Prices expected to stabilize around $30-$40 per 30-count in the next five years.
Key Takeaways
- The patent expiry in 2014 transitioned the drug to a highly competitive generic market.
- Current prices for generic duloxetine are around $45 per 30-count, with modest downward trends forecasted.
- Market demand remains stable, driven by entrenched indications and insurance coverage.
- Future price reductions are limited due to the mature, commoditized market.
FAQs
1. What factors could disrupt the current price trends for duloxetine?
Introduction of new formulations, additional biosimilars, or regulatory restrictions on off-label uses could affect market dynamics.
2. How does the competition affect pricing strategies?
High generic penetration constrains prices due to increased supply and reduced brand-market power, forcing manufacturers to compete primarily on price.
3. Are there significant regional differences in pricing?
Yes. Prices tend to be higher in rural or underserved areas due to distribution costs and insurance coverage nuances.
4. Can off-label uses influence the market size or pricing?
Yes. Off-label prescribing in pain management maintains or increases demand, which can support stable prices despite generic competition.
5. What is the outlook for brand-name duloxetine?
Brand-name Cymbalta's market share diminished significantly post-patent expiry. Its availability persists mainly in select regions or for specific formularies, with prices comparable to or exceeding generics.
Sources
[1] IQVIA. (2022). IQVIA National Prescription Audit.
[2] FDA. (2015). Approval of Generic Duloxetine.
[3] Federal Trade Commission. (2017). Antitrust considerations in generic drug markets.
[4] Statista. (2022). U.S. antidepressant sales.
